(24/7 MARKET NEWS) – BridgeBio Pharma, Inc. (Nasdaq: BBIO) is booming after announcing, this morning, positive PROPEL2 Phase 2 trial data, of the investigational therapy infigratinib in children with achondroplasia, demonstrating potential best-in-class efficacy and a clean safety profile.
BridgeBio Pharma is at $16.86, up $5.99 (+55.10%), on 1.2 million premarket shares.
Its 52-week trading range is $4.98 to $13.11. It’s close to begin filling in the gap to near the forty-dollar level, from 2022.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
